Adjunctive Dapagliflozin Improves Glycemic Control in T1D
Dapagliflozin, when used as adjunct treatment to insulin, improves glycemic control in patients with type 1 diabetes.
The FDA has granted Orphan Drug Designation to PCS499 (Processa Pharmaceuticals) for the treatment of necrobiosis lipoidica.
U.S. officials need to take action to control spiking insulin prices, the American Medical Association says.
Although metformin has been studied in randomized trials as adjunctive therapy to insulin in individuals with type 1 diabetes, further investigation in the form of outcomes trials is necessary to ...